Cubist’s Sivextro To Beat Durata’s Dalvance To Antibiotic Market
This article was originally published in The Pink Sheet Daily
Second QIDP antibiotic is first to market; Cubist will stress shorter term dosing over available therapies and thinks it can rely on efficient marketing strategy for commercial success.
You may also be interested in...
Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.
Company plans to file an NDA for the antibiotic in September, built partly on clinical work done by the drug’s previous owner, Pfizer. Given hospitals’ emphasis on cost, Durata’s marketing plan will highlight the drug’s two-dose regimen, which could help move treatment to the ambulatory-care setting.
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.